Ho and colleagues test a multifaceted intervention to improve cardiac medication regimen adherence and secondary prevention measures. Redberg provides an Editor’s Note.
This cohort study assesses the association between changes in Centers for Medicare & Medicaid Services reimbursement policy and erythrocyte-stimulating agent drug labels with outcomes for patients undergoing hemodialysis.
Cheng et al conduct a meta-analysis to separately evaluate the effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and major cardiovascular events in patients with diabetes mellitus.
This population-based study examines the incidence of all-cause mortality, cardiovascular disease, and cancer in individuals with type 2 diabetes based on socioeconomic status.
This analysis examines whether asymptomatic bradycardia in patients without cardiovascular disease is associated with a lower cardiovascular risk profile, less subclinical atherosclerosis, and decreased incident CVD and mortality.
This US data registry study finds that neither fibrinolysis nor primary percutaneous coronary intervention is being optimally used to achieve guideline-recommended reperfusion targets in patients with ST-segment elevation myocardial infarction. See the Invited Commentary by Claeys.